智飞生物早盘大涨6.7%,注射液获得临床试验批准。
Group 1 - The core point of the article is that Zhifei Biological experienced a significant stock increase of 6.7% following the approval of its injection solution for clinical trials [1] Group 2 - The approval of the clinical trial is a positive development for the company, indicating progress in its product pipeline [1] - The market reaction reflects investor confidence in the company's future prospects following this regulatory milestone [1]